Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.13, $0.16 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $49.14 million versus the consensus estimate of $49.44 million.

GUIDANCE:

Vanda reiterates 2018 net product sales guidance of $180 million to $200 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.